Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It appears in many of the same metabolic research discussions as peptide compounds, and the query “5 amino 1mq” is often typed alongside peptide searches, but the molecule is not a peptide at all. It is a methylated quinolinium compound with a fused aromatic ring system, closer in character to a classical medicinal-chemistry probe than to a chain of amino acids. That distinction shapes how it is designed, how it works, and how it is handled at the bench.
This article explains what 5-Amino-1MQ is, how NNMT inhibition is studied to act on the intertwined chemistry of cellular methylation and NAD+ salvage, and what the preclinical literature through 2026 reports in adipocyte and diet-induced obesity models. It also sets the compound against direct NAD+ precursors and against the peptide reagents it is often shelved beside. Everything described here is provided for research use only, not for human consumption, and reflects work in enzymes, cultured cells, and laboratory animals rather than any clinical setting.
What Is 5-Amino-1MQ, and Why It Is Not a Peptide
A quinolinium small molecule
Peptides are chains of amino acids joined by amide bonds; their identity is described by a sequence and their masses run from a few hundred daltons for a tripeptide to several kilodaltons for larger chains. 5-Amino-1MQ has none of that architecture. It is a single quinolinium ring system carrying a methyl group at the N-1 position and an amino group at the 5-position, supplied as a crystalline salt rather than a lyophilized peptide cake. Its design is deliberately a product mimic: NNMT produces 1-methylnicotinamide, a methylated heterocycle, and the methylquinolinium scaffold imitates that product to occupy the enzyme’s active site.
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported Value |
|---|---|
| Compound class | Small-molecule quinolinium (not a peptide) |
| Chemical name | 5-amino-1-methylquinolinium |
| Cation formula | C10H11N2+ |
| Approx. MW (free cation) | ~159.2 g/mol |
| Common salt form | Iodide, C10H11N2I (~286.1 g/mol) |
| Molecular target | Nicotinamide N-methyltransferase (NNMT) |
| Mechanistic class | Cell-permeable, product-mimicking NNMT inhibitor |
Because it is a small molecule, its identity is confirmed differently from a peptide. Rather than sequence confirmation, a research-grade lot is characterized by HPLC purity, mass spectrometry, and nuclear magnetic resonance to establish the ring substitution pattern, with Karl Fischer titration for water content so that concentrations are accurate. The general principles of reading purity and identity data still apply, and the COA reading guide is a useful starting point even for a non-peptide reagent.
How NNMT Inhibition Works
NNMT catalyzes a single reaction with outsized consequences. It transfers a methyl group from S-adenosylmethionine (SAM), the cell’s primary methyl donor, onto nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. The enzyme is highly expressed in liver and adipose tissue, and it sits at a junction between two metabolic systems that most enzymes touch only one of.
The dual axis: methylation and NAD+ salvage
Inhibiting NNMT has two coupled effects. First, less SAM is consumed, which raises the cellular SAM to SAH ratio and, in principle, supports the many methyltransferase reactions that draw on SAM, from histone and DNA methylation to phospholipid synthesis. Second, less nicotinamide is diverted into methylation, leaving more of it available to the NAD+ salvage pathway, the main route of NAD+ regeneration in most mammalian tissues. A compound that simultaneously nudges methylation potential up and preserves an NAD+ precursor is unusual, and this dual character is the reason NNMT attracts interest as a metabolic research target rather than a single-pathway enzyme.
Product mimicry and selectivity
The mechanistic appeal of 5-Amino-1MQ is that it is cell-permeable and reasonably selective. Bisubstrate analogs that bridge the SAM and nicotinamide sites bind NNMT tightly but often cross membranes poorly, while broadly SAM-competitive inhibitors risk hitting the many other methyltransferases that share SAM-binding folds. The product-mimicking quinolinium class threads between those problems. A 2025 study in the Journal of Biological Chemistry characterized the mechanism and kinetics of turnover inhibitors of NNMT in vitro and in vivo, part of a maturing effort to define exactly how this enzyme is engaged, and reviews of the field describe selectivity against related methyltransferases as a key property of the quinolinium probes.
5 Amino 1MQ in Metabolic Research
The preclinical record begins with target validation. A 2014 study in Nature reported that knocking down NNMT protected mice from diet-induced obesity and increased energy expenditure, establishing the enzyme as a candidate metabolic target. That result set the stage for inhibitor work, and 5-Amino-1MQ emerged as a lead cell-permeable compound characterized in Biochemical Pharmacology in 2018, where diet-induced obese mice given the inhibitor showed reductions in body mass and white adipose tissue in the reported models, without changes in food intake.
Adipocyte and liver models
In cultured adipocytes, NNMT inhibition has been associated with lower intracellular 1-methylnicotinamide and higher NAD+, consistent with the salvage-preservation half of the mechanism. The enzyme’s strong expression in liver has extended the work into hepatic models, where NNMT has been tied to nutrient handling through pathways including Sirt1 stabilization. A 2025 report in Nature Communications described an NNMT and 1-methylnicotinamide axis in hepatic ischemia-reperfusion injury, illustrating how the same enzyme is probed across several tissue contexts.
Widening scope through 2026
NNMT research has broadened well beyond adipocytes. The enzyme is over-expressed in several tumor types, where it is studied as a metabolic methylation sink, and 2025 to 2026 literature has examined it in cancer-associated fibroblasts, cardiovascular tissue, and skeletal muscle. A 2026 review in Trends in Pharmacological Sciences surveyed emerging opportunities for NNMT inhibitor translation, and NAD+ metabolism reviews from 2025 place NNMT within the wider control of cellular NAD+ and mitochondrial function. The practical takeaway is that 5-Amino-1MQ has become a general-purpose chemical-biology tool for questions about methyl-group flux and NAD+ balance, not only about fat cells. The phrase research use only, not for human consumption applies to every one of these model systems.
Comparators: Small Molecule Versus Peptide, and NNMT Versus Direct Precursors
Placing 5-Amino-1MQ next to the reagents it is often catalogued beside clarifies what it uniquely offers. The comparison below spans both the NAD+ research landscape and the peptide reagents that share those shelves. These values reflect commonly reported laboratory attributes and are provided for comparison only.
| Research compound | Chemical class | Point of action on NAD+ or methylation |
|---|---|---|
| 5-Amino-1MQ | Small-molecule quinolinium | Inhibits NNMT; preserves nicotinamide and raises SAM:SAH |
| NAD+ | Dinucleotide | Direct cofactor, studied as a supplied pool |
| NMN / NR | Nucleotide / nucleoside | Direct salvage-pathway precursors, upstream of NAD+ |
| MOTS-c | Mitochondrial-derived peptide | AMPK-linked metabolic signaling, a peptide comparator |
Two contrasts matter. Against direct precursors such as NAD+ or its building blocks NMN and NR, which feed the pathway from upstream, 5-Amino-1MQ works by conserving nicotinamide already in the cell, so pairing the approaches lets investigators separate precursor supply from salvage flux. Against peptide reagents such as MOTS-c, the difference is chemical: a small molecule is handled and characterized by different standards, and its counter-ion and intrinsic fluorescence are variables a peptide does not introduce. Both distinctions make 5-Amino-1MQ a useful, clearly non-peptide member of the metabolic research catalog.
Handling notes
As a crystalline salt, 5-Amino-1MQ is stored dry, cool, and protected from light, and stock solutions are prepared in the solvent the assay requires, then aliquoted so freeze-thaw cycles are minimized. Its small-molecule nature makes it less fragile than many peptides, but the same discipline around aliquoting and documentation applies; the storage and handling guide covers the shared principles.
Frequently Asked Questions
What is 5 amino 1mq?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is a methylated quinolinium compound, not a peptide, studied as a cell-permeable chemical-biology tool in metabolic research. It is supplied for research use only, not for human consumption.
Is 5-Amino-1MQ a peptide?
No. Despite being catalogued alongside metabolic peptides, 5-Amino-1MQ is a small-molecule organic compound built on a quinolinium ring, with a molecular weight near 159 g/mol for the free cation. It has no amino acid sequence and is handled by small-molecule rather than peptide standards.
How does 5-Amino-1MQ work on NNMT?
It mimics 1-methylnicotinamide, the product NNMT makes, and occupies the enzyme’s active site. Inhibiting NNMT reduces consumption of both S-adenosylmethionine and nicotinamide, which raises the cellular SAM to SAH ratio and preserves nicotinamide for NAD+ salvage in the models studied.
What has preclinical research on 5-Amino-1MQ shown?
Foundational work characterized it as a selective, cell-permeable NNMT inhibitor and reported reductions in body mass and white adipose tissue in diet-induced obese mice. Later studies extended NNMT research into liver, cardiovascular, skeletal muscle, and cancer models through 2026. All findings are preclinical.
How does 5-Amino-1MQ differ from NMN or NR?
NMN and NR are direct NAD+ precursors that feed the salvage pathway from upstream. 5-Amino-1MQ acts differently, by inhibiting NNMT so that nicotinamide already present is preserved for NAD+ synthesis. The approaches are complementary and are sometimes combined in mechanistic studies.
Is 5-Amino-1MQ intended for human use?
No. 5-Amino-1MQ is supplied for laboratory research use only, not for human consumption or self-administration. The information here describes enzyme, cell-culture, and animal-model research and does not describe any human application.
References and Further Reading
- Kraus D and colleagues on NNMT knockdown protecting mice from diet-induced obesity (Nature, 2014). PubMed: nicotinamide N-methyltransferase knockdown diet-induced obesity
- Neelakantan H and colleagues on membrane-permeable small-molecule NNMT inhibitors in obese mice (Biochemical Pharmacology, 2018). PubMed: membrane-permeable small molecule NNMT inhibitor obesity mice
- Pissios P on NNMT biology beyond vitamin B3 clearance (Trends in Endocrinology and Metabolism, 2017). PubMed: nicotinamide N-methyltransferase Pissios metabolism
- Roberti A, Fernandez AF, and Fraga MF on NNMT at the crossroads of metabolism and epigenetics (Molecular Metabolism, 2021). PubMed: NNMT crossroads cellular metabolism epigenetic regulation
- Mechanism and kinetics of turnover inhibitors of NNMT in vitro and in vivo (Journal of Biological Chemistry, 2025). PubMed: mechanism kinetics turnover inhibitors nicotinamide N-methyltransferase
- Puleo N, Lengyel E, and colleagues on emerging opportunities for NNMT inhibitor translation (Trends in Pharmacological Sciences, 2026). PubMed: emerging opportunities nicotinamide N-methyltransferase inhibitor
- Reviews of NAD+ metabolism and mitochondrial modulation in aging and disease (2025). PubMed: NAD metabolism mitochondria aging disease review
